Background. The UK national policy promotes expansion of home haemodialysis, but there are no recent data on characteristics and outcomes of a national home haemodialysis population. Methods. We compared incident home haemodialysis patients in England and Wales (n = 225, 1997-2005) with age-and sex-matched incident peritoneal dialysis, hospital haemodialysis and satellite haemodialysis patients with follow-up until 31 December 2006. Cox regression analyses included time-dependent changes of wait-listing for transplantation (a proxy for health status), start of home haemodialysis and transplantation.
Introduction
Interest in home haemodialysis has revived, partly, due to evidence suggesting its cost-effectiveness [1] , but also to the advent of newer modalities such as short daily and long nightly haemodialysis which are more easily delivered in a patient's home and which may improve outcomes compared with conventional thrice-weekly dialysis. In some countries, prevalence of home haemodialysis has risen-reversing the declining trend since the 1980s [2, 3] .
Small studies of conventional thrice-weekly home haemodialysis in the 1970s-90s demonstrated better survival compared with hospital haemodialysis [4] [5] [6] and peritoneal dialysis [7] , even after adjustment for various factors known to affect survival. However, there are few, if any, studies reporting the characteristics and outcomes of a national home haemodialysis population in the current era.
We examined baseline characteristics and outcomes in a large, incident population of home haemodialysis patients in England and Wales, and compared them with incident peritoneal dialysis, hospital haemodialysis and satellite haemodialysis patients.
Materials and methods
All patients who commenced on home haemodialysis from 1 January 1997 until 31 December 2005 were identified from the UK Renal Registry (UKRR) database. Details of the UKRR data collection and validation procedures have been summarized elsewhere [8] . The UKRR coverage of the UK renal replacement therapy (RRT) population from 1997 to 2005 is shown in Table 1 .
Hospital haemodialysis was defined as haemodialysis provided by a dialysis unit with renal inpatient facilities on the same site. Satellite haemodialysis was defined as haemodialysis provided by a dialysis unit with no inpatient renal facilities on-site. In the UK, these units are looked after by peripatetic nephrologists and typically have no on-site renal doctors [9] . Home haemodialysis patients are patients who started home haemodialysis after start of RRT (median delay: 12 months).
The dates of the decision to train a patient for home haemodialysis were not available. We used an algorithm that matched patients who started RRT and later went on home haemodialysis with patients on peritoneal dialysis, or haemodialysis in satellite units or hospitals, who survived at least 90 days after commencing RRT. Matching the start of observation period on Day 90 was to identify a healthier cohort of patients, more comparable with the home haemodialysis (HD) patients. Patients who recovered within 90 days are by definition not included in the take-on cohort. We decided against matching on start of home haemodialysis because this would be matching on an event in the future and, when seen from the perspective of patients who are not offered home haemodialysis, would ignore the mortality during the first year on dialysis.
Because this cohort of patients was much younger than the general incident RRT population, it was difficult to identify individually matched controls in the same centre and year implying that this would need to be controlled for by analysis. Using frequency matching for age (using bands: 18-34, 35-44, 45-54, 55-64, 65-74, 75-84 and 85+ years old) and gender, we identified incident control patients (four hospital haemodialysis patients, four peritoneal dialysis patients and two satellite haemodialysis patients per home haemodialysis patient). Patients younger than 18 years old were excluded. If more than the required number of controls were available, a computerized random number generator was used to randomly select the required number of controls.
Baseline and follow-up data Baseline data were collected from all subjects and controls including age, sex, primary renal disease, ethnicity, Townsend deprivation scores [10] , estimated GFR (eGFR) at start, dialysis modality at baseline, blood pressure (post-dialysis in haemodialysis patients), ultrafiltration volume (in haemodialysis patients), haemoglobin, phosphate, serum albumin (and type of assay used) and year of start of RRT. Blood samples were predialysis samples in haemodialysis patients. eGFR immediately prior to the first RRT was calculated using the four-variable Modification of Diet in Renal Disease (MDRD) formula [11] .
Follow-up data were collected until 31 December 2006, and these included date of death, date of recovery of kidney function, date of loss to follow-up, dates of wait-listing for transplantation, and modality changes (including transplantation). In the UK, patients are put on the waiting list for transplantation, if they are deemed suitable and ready for transplantation. Patients are not deemed suitable for transplantation if they recently had cancer or serious (and untreated) heart problems which would require intervention first. Thus, in the UK context, the date of wait-listing for transplantation is informative on the health status of a patient, with patients on the waiting list being generally of better health when compared with patients with the same dialysis vintage who are not on the waiting list. There remains variation of listing between centres which is not explained by primary renal disease [12] , which implies that the date of listing in the analysis will also proxy for centre differences in patient management.
Statistical analysis
Descriptive data analysis used Fisher's exact and chi-square tests, linear and logistic regression analysis, and Kruskal-Wallis tests where appropriate. Missing data in covariates are mentioned in the results section for each analysis separately. Descriptive analysis of time to wait-listing for kidney transplantation, modality survival and survival was carried out using Kaplan-Meier graphs, calculating crude rates and log-rank testing. Censoring for death was performed at the end of the observation period or at the end of follow-up (31 December 2006) except for patients who recovered within a year of starting their dialysis (n = 18, none on home haemodialysis).
We adjusted for date of home haemodialysis start using a timedependent variable to avoid immortal time bias [13] . Otherwise, patients who subsequently started home haemodialysis would have been assumed to be on that modality from Day 90 onwards. Immortal time bias occurs, if the group of interest (here the home haemodialysis patients), by default, lives longer (due to the considerable delay in starting home haemodialysis after Day 90) than the comparison groups (the patients on the other dialysis modalities at Day 90 of RRT). This is displayed schematically in Figure 1 . We also took into account the wait-listing date and date of transplantation using time-dependent variables. Censoring patients after kidney transplantation would have selectively removed those with a better survival outcome and thus invalidated the modality comparisons before transplantation. All adjusted models included terms for age, sex, primary renal disease, and year of start of dialysis. Proportionality of hazards in Cox models was investigated using graphical methods and Schoenfeld residual testing. An interaction term was included for diabetes and age, as diabetic nephropathy in the older group had a less detrimental impact [14] . Final multivariable Cox models were adjusted for clustering in-centre using robust standard errors. This method adjusts the standard errors, P-values and confidence intervals in imbalances of patient numbers between different renal centres. Analyses were carried out with Stata 10 [15] .
Results

Baseline description of patients on home haemodialysis
Between 1997 and 2005, 225 patients from the UKRR population commenced treatment with home haemodialysis. Baseline characteristics for these patients and the matched control patients are shown in Table 2 . Compared with the control groups, home haemodialysis patients were more likely to be white, less likely to be socially deprived, more likely to have glomerulonephritis or polycystic kidney disease, and less likely to have diabetic nephropathy or hypertensive nephropathy. There was a median delay of 12 months (interquartile range 6-21), between patients starting RRT and commencing home haemodialysis. At Day 90 after starting RRT, only 33 of those who trained for home haemodialysis were on that modality, with 128 on hospital haemodialysis, 28 on satellite haemodialysis and 24 on peritoneal dialysis, and 2 had failing transplants. The other groups were, by definition, on the specified modality at Day 90.
To provide overall context, there were 28 464 incident RRT patients in the total UKRR database over this time period (Table 1) , and these patients tended to be much older and included more women: 48% were 65 years and above, 62% were male, and 88% were white. At Day 90 Outcomes in patients on home haemodialysis in England and Walesafter starting RRT, 60.3% were treated with hospital haemodialysis, 6.3% satellite haemodialysis, 0.9% home haemodialysis, 0.9% unknown type of haemodialysis and 31.6% peritoneal dialysis. Baseline blood pressure (Day 90) was similar across the groups, except that diastolic blood pressure was slightly lower in the home haemodialysis group compared with patients on peritoneal dialysis (Table 3) . Serum albumin was higher in the patients who subsequently went on to home haemodialysis, and lower in patients on peritoneal dialysis. Pre-dialysis serum phosphate was similar across the haemodialysis groups, but was lower in the peritoneal dialysis patients, with the converse pattern being evident for haemoglobin.
Modality survival
Home haemodialysis patients continued treatment for a median duration of 18 (interquartile range 9-33) months. There were 3 patients who had only 1 quarter with home haemodialysis recorded and further 11 who were censored after more than 2 quarters-this occurred presumably because these 14 patients moved to a centre not submitting data to the UKRR at the time. There were 81 patients on home haemodialysis who were alive at the end of the observation period (31 December 2006). A crude Kaplan-Meier modality survival curve is displayed in Figure 2 . There were 130 patients with known reasons for stopping home haemodialysis: 77 patients underwent kidney transplantation (35%), 27 switched to hospital haemodialysis (12%), 3 to satellite haemodialysis (4%) and 1 to peritoneal dialysis (crude rates are displayed in Table 4 ). Twenty-two (10%) patients died, 19 of whom died after switching to another modality within 3 months after the last recorded quarter of home HD.
Wait-listing for kidney transplantation
Some patients were wait-listed for kidney transplantation prior to commencing RRT (home haemodialysis 12.9%, hospital haemodialysis 6.3%, satellite haemodialysis 7.3% and peritoneal dialysis 10.0%; bottom of Table 2 ). After adjusting for age, gender, primary renal disease, ethnicity, and social deprivation and incorporation of an in-centre clustering term (logistic regression) suggested that there is borderline significance that hospital haemodialysis patients are less likely to be wait-listed before starting RRT (OR 0.54, 95% CI 0.27-1.09; P = 0.084).
Using unadjusted data, patients subsequently treated with home haemodialysis were more likely to be waitlisted for kidney transplantation after starting RRT, and were wait-listed sooner than hospital or satellite haemodialysis patients. As can be seen in Figure 3 , the cumulative proportion of wait-listing for satellite patients first increases at a similar speed compared with hospital haemodialysis patients in the first 6 months (overlapping curves). However, after some time on dialysis, the curves diverge, and those on hospital haemodialysis are wait-listed faster when compared with those in satellite units. A Cox regression model was developed to assess wait-listing further, allowing for a centre effect and incorporating terms for year of start, age, gender, primary renal disease, ethnicity, and social deprivation (top of Table 5 ). In fully adjusted analyses, patients on hospital haemodialysis were less likely than home haemodialysis patients to be listed for kidney transplantation during RRT, but there was no evidence for a difference between home haemodialysis and peritoneal dialysis.
Mortality
Death occurred in 662 patients (26.7%) over follow-up. Unadjusted survival analysis shows a significant survival benefit for the home haemodialysis patients over the other modalities (Figure 4 , log-rank P < 0.001). The poorest crude survival was in hospital haemodialysis patients with very high early mortality-their 1-year survival was 90% (95% CI 87-91%) while home haemodialysis patients of similar age and sex had 97% 1-year survival (95% CI 94-99%). One-year survival of peritoneal dialysis patients was 95% (95% CI 93-96%) which was similar to satellite haemodialysis patients 95% (95% CI 92-96%).
A Cox regression model for time from starting RRT to death was generated including a time-dependent variable for date of start of home haemodialysis, and baseline Modality survival of home haemodialysis patients Fig. 2 . Crude modality survival of home haemodialysis since starting home haemodialysis (corresponding rates are in Table 4 ). Table 5 ), and (ii) comparing those on home haemodialysis with satellite haemodialysis and peritoneal dialysis patients (bottom of Table 5 ). When we took into account the 12 months lag between starting RRT and actually starting haemodialysis at home using the time-dependent variable, we found that satellite dialysis and home haemodialysis offered a similar survival advantage with~30% decrease of the hazard of death when compared with surviving patients on hospital haemodialysis. The effect of the time-dependent variable for home haemodialysis did not reach conventional levels of statistical significance, but the confidence intervals include a majority of values below 1, suggesting that there may be a beneficial effect of being on home haemodialysis as opposed to dialysing in the hospital.
Compared with patients on peritoneal dialysis, being on home haemodialysis yielded a long-term survival benefit [hazard ratio (HR) 0.61, 95% CI 0.40-0.93]. This analysis did not have enough power to tease out whether there was a survival advantage of satellite haemodialysis relative to peritoneal dialysis (HR 0.94, 95% CI 0.65-1.37) as can be seen by the wide confidence intervals. When satellite haemodialysis is directly compared with home haemodialysis, there was no evidence of a survival benefit or disadvantage of home haemodialysis (HR 1.06, 95% CI 0.55-2.04), and wide confidence intervals indicate low power.
Discussion
In a large incident population from across England and Wales, we found home haemodialysis was uncommon (< 1%). The few patients who eventually started home haemodialysis had a substantial crude survival advantage compared with controls initially treated with hospital haemodialysis, satellite haemodialysis or peritoneal dialysis with similar age and sex distribution (who were never put on home haemodialysis). Home haemodialysis patients were more likely to be white, less likely to be socially deprived, less likely to have higher risk primary renal diseases and more likely to be put on the waiting list for kidney transplantation, and had higher baseline serum albumin even before starting home haemodialysis. All of these differences, with the exception of ethnic origin, would be associated with improved outcomes, suggesting a very strong element of selection. The survival advantage persisted after multivariable analysis compared with peritoneal dialysis. Survival was also better than with hospital haemodialysis, but did not achieve significance. The study's power was insufficient to reach a conclusion in the comparisons with satellite haemodialysis. For technical reasons, the multivariable analysis could not directly compare peritoneal dialysis and hospital haemodialysis. Similar findings with regard to non-proportionality have been reported before [16, 17] .
A multi-centre US study examined a sample of 70 incident home haemodialysis patients who started dialysis in 1986-87, and compared them to centre-based haemodialysis patients over 4 years follow-up using an intention-to-treat approach, and censoring for transplant- Fig. 3 . Crude cumulative rates of patients who are being wait-listed over time (in years after starting renal replacement therapy). Analyses are excluding those who were already wait-listed before renal replacement therapy start (log-rank P-value < 0.0001 for home haemodialysis compared with those on other modalities).
ation [5] . They demonstrated that home haemodialysis patients were younger, more likely to be white and male, and less likely to have diabetic nephropathy, and had fewer comorbidities. Cox regression revealed an adjusted HR of 0.66 (95% CI 0.43-1.02) for mortality, and became significant when patients not dialysing at home by 30 days were excluded. The majority of our patients would have been excluded from this US study, as they started home haemodialysis after 30 days. A single-centre Swiss study compared 58 patients who commenced home haemodialysis in 1970-1995 to in-centre haemodialysis patients matched for age, sex, primary renal disease and dialysis start date [6] . Home haemodialysis had a superior survival rate at 5, 10 and 20 years of follow-up, and the advantage persisted after multivariable analysis. Based on case note review, there was adjustment for a comorbidity index. Patients in the UK started later than currently advocated in the literature; however, it may be that the UK is not an exception. A recent study from Canada has found that their home haemodialysis patients arrived at the decision to start home haemodialysis after a mean duration of 4.8 ± 6.8 years of RRT [18] . Change in modality occurred largely due to kidney transplantation. This does question the economic model used for justification of home haemodialysis expansion [1] . However, before drawing conclusions against home haemodialysis, reasons for this late start need to be explored in more detail.
Ours is the first study to compare home haemodialysis with centre and satellite haemodialysis separately. Satellite haemodialysis has expanded substantially in the UK, and by reducing travel time, it reduced one of the advantages of home haemodialysis for patients, so this was an important group to assess. The difference in wait-listing patterns over time may suggest that patients in satellite units are less healthy than home haemodialysis patients. Alternatively, wait-listing patterns over time may reflect quality of care of different centres (and the decision to start patients on satellite haemodialysis). Once this is taken into account in the adjusted analyses, there was no clear evidence for a survival advantage for those on home haemodialysis relative to those in satellite units, but power was limited due to the small number of available satellite haemodialysis patients of similar young age as the home haemodialysis population. Given the expansion in satellite dialysis services, further assessment in the future may be informative.
In a two-centre Scottish study, 139 patients who started home haemodialysis between 1982 and 1988 had a 7.6% Table 5 . Cox regression models of time from commencing renal replacement therapy till wait-listing and death with HR and their 95% confidence intervals (adjusted for centre effect, year of start, age, gender, primary renal disease, ethnicity and social deprivation) Outcomes in patients on home haemodialysis in England and Walesbetter 3-year survival than age-and sex-matched controls on peritoneal dialysis [7] . The home haemodialysis population had less comorbidity. Similar findings have been reported from Australasia [17, 19] . Our study is in line with previous findings of better outcomes with home haemodialysis than peritoneal dialysis in a larger, more recent, multicentre population, and using multivariable analysis. Our study has limitations. The groups are not randomized. Genuine randomization to home or centre dialysis is difficult, as demonstrated by the recruitment difficulties in the Frequent Haemodialysis Network trials [20] . Also, our study is retrospective and registry-based, so we were unable to fully characterize comorbidity. Nevertheless, others have suggested that comorbidity adds relatively little to the variance in mortality of RRT patients once age, gender and primary renal disease are included [21] . Furthermore, we used wait-listing for kidney transplantation as an indirect marker of health of patients in a given centre. This may represent a more global assessment of health by the physicians looking after the patient at the time, compared with a retrospectively applied comorbidity score. We did not adjust crude data for centre effects. However, P-values and confidence intervals of the fully adjusted analyses took into account clustering of patients in centres. Finally, in the UK, patients did not generally start home haemodialysis at the outset of RRT. By exposing patients in the home haemodialysis group to the other dialysis modalities, this may have reduced our ability to detect differences between the therapies.
Why do home haemodialysis patients survive longer? There are three likely causes. First, there is substantial selection bias, such that only the healthiest patients are commenced on home haemodialysis. We have attempted to account for that using control patients who were frequency-matched for age and sex and a time-dependent variable that took into account the starting quarter of home haemodialysis. We also used adjustment for confounding variables within a multivariable analysis that incorporated wait-listing for transplantation as a time-dependent variable. Other studies have used different statistical approaches and still found a survival advantage, but the risk of residual confounding remains in all such observational studies.
Second, haemodialysis at home may allow increased treatment (whether increased frequency or duration), which may be associated with improved survival. An anecdote suggests that patients often add additional dialysis sessions. Recent observational studies have shown that both short daily [22, 23] and long nightly home haemodialysis [24] are associated with increased survival, even when compared to deceased-donor kidney transplantation. One plausible mechanism for this is reduction in left ventricular mass [25, 26] . None of our patients was treated with long nightly haemodialysis, and few, if any would have been treated with short daily haemodialysis, as this was not widely used in the UK at this time.
Third, social or psychological factors may explain the survival advantage. The data show that patients on home haemodialysis are from less deprived areas. This may be partly related to feasibility of adapting homes to the technology, and the recent support for home haemodialysis [27] was not available at the time of this study. Our use of area deprivation scores probably underestimates the true gradient in use of home haemodialysis. Given the social gradient in home haemodialysis provision, there is a risk that expansion of home haemodialysis may increase inequities of provision in different social groups. In terms of psychological factors, it may be that engagement of patients with their treatment enhances understanding and improves adherence.
In conclusion, we have shown improved survival for home haemodialysis compared with peritoneal dialysis. It is difficult to exclude selection bias completely, but we believe this study supports the current drive to offer home haemodialysis to patients who want to dialyse outside hospital. Randomized trials of dialysis modalities are unlikely to address patient survival, but prospective observational studies on home compared with satellite haemodialysis may add further to our understanding, by careful documentation of baseline and follow-up characteristics.
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